45 related articles for article (PubMed ID: 31874475)
1. Role of endometrial sampling to differentiate between advanced endometrial versus ovarian malignancy: retrospective cohort study.
Nguyen NTT; Diaz N; Reid H; Previs R; Havrilesky LJ; Secord AA; Berchuck A
Int J Gynecol Cancer; 2024 Apr; 34(4):528-534. PubMed ID: 38336373
[TBL] [Abstract][Full Text] [Related]
2. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
3. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
4. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Zhu Y; Yang J
J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies.
Jeon J; Kim SE; Lee DY; Choi D
Breast Cancer Res Treat; 2020 Jan; 179(1):125-130. PubMed ID: 31541382
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of influencing factors of endometrial disease of patients with breast cancer after operation].
Pan NP; Zhou WX; Tang J; Zhou JH; Li JQ
Zhonghua Fu Chan Ke Za Zhi; 2019 Dec; 54(12):848-853. PubMed ID: 31874475
[No Abstract] [Full Text] [Related]
7. Benign and malignant diseases of the endometrium.
Chaudhry S; Reinhold C; Guermazi A; Khalili I; Maheshwari S
Top Magn Reson Imaging; 2003 Aug; 14(4):339-57. PubMed ID: 14578778
[No Abstract] [Full Text] [Related]
8. The endometrial effects of SERMs.
Cano A; Hermenegildo C
Hum Reprod Update; 2000; 6(3):244-54. PubMed ID: 10874569
[TBL] [Abstract][Full Text] [Related]
9. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
11. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
